ANEB - Anebulo Pharmaceuticals Inc

ANEB - Anebulo Pharmaceuticals Inc

https://www.anebulo.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug - Anebulo Pharmaceuticals ( NASDAQ:ANEB )

Benzinga • 1 year, 7 months ago • score: 0.17

The biopharmaceutical company Anebulo Pharmaceuticals, Inc. ANEB reported its second quarter financial results on Tuesday for the three months ended Dec. 31, 2023, The company's primary focus is on developing therapy for acute cannabinoid intoxication ( ACI ) .

Are Medical Stocks Lagging Anebulo Pharmaceuticals ( ANEB ) This Year?

Zacks Commentary • 1 year, 10 months ago • score: 0.36

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Exact Sciences ( EXAS ) This Year?

Zacks Commentary • 1 year, 11 months ago • score: 0.24

Here is how Exact Sciences (EXAS) and Anebulo Pharmaceuticals, Inc. (ANEB) have performed compared to their sector so far this year.

Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says - Anebulo Pharmaceuticals ( NASDAQ:ANEB )

Benzinga • 1 year, 11 months ago • score: 0.09

H.C. Wainwright has initiated coverage on Anebulo Pharmaceuticals Inc ANEB with a Buy rating and a price target of $6.

Anebulo ( ANEB ) Gains on Positive FDA Response for ANEB-001

Zacks Commentary • 2 years ago • score: 0.17

Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.

Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication - Anebulo Pharmaceuticals ( NASDAQ:ANEB )

Benzinga • 2 years ago • score: 0.19

Anebulo Pharmaceuticals, Inc. ANEB announced positive feedback from the United States Food and Drug Administration following a type B meeting in July.

Is Anebulo Pharmaceuticals ( ANEB ) Outperforming Other Medical Stocks This Year?

Zacks Commentary • 2 years, 3 months ago • score: 0.43

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. The company is headquartered in Lakeway, Texas.

52W High

$3.42

52W Low

$0.80

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.89

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-6.54

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

7.26

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

40.54%

Institutions (25–75% balanced)

54.99%

Shares Outstanding

41,084,700

Float

3,401,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.25

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.83%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0808

Previous

-0.0987

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025